Research Article
Serum and Urine Neutrophil Gelatinase-Associated Lipocalin Levels Measured at Admission Predict Progression to Chronic Kidney Disease in Sepsis-Associated Acute Kidney Injury Patients
Table 3
Comparison of demographic and laboratory characteristics, serum NGAL, urine NGAL in AKI to CKD patients, and completely recovered patients.
| | Clinical characteristics and laboratory parameters | AKI to CKD patients () | Recovery patients () | |
| | Ages | | | 0.039 | | Number of male (, %) | 17 (63) | 55 (58.5) | 0.678 | | Hypertension (, %) | 11 (40.7) | 32 (34) | 0.522 | | Diabetes mellitus (, %) | 9 (33.3) | 22 (23.4) | 0.298 | | Blood urea (mmol/l) | 25.2 (16.7–32.8) | 9.55 (7.05–14.12) | <0.001 | | Creatinine (μmol/l) | 326 (235–435) | 166 (150–199.25) | <0.001 |
| | (i) Stage I | 6 (22.2) | 77 (81.9) | <0.001 | | (ii) Stage II | 12 (44.4) | 16 (17) | | (iii) Stage III | 9 (33.3) | 1 (1.1) | | eGFR (ml/min/1.73m2), median | 15 (11–21) | 29 (24–39) | <0.001 | | Oliguria (, %) | 17 (63) | 28 (29.8) | 0.002 | | WBC (G/l), median | 15.61 (14.2–18.86) | 14.91 (12.75–19.74) | 0.627 |
| | >12 G/l (, %) | 25 (92.6) | 77 (81.9) | 0.179 |
| | <4 G/L (, %) | 2 (7.4) | 77 (18.1) | 0.179 | | Neutrophil (G/l), median | 12.31 (10.2–16.12) | 11.81 (9.9–16.05) | 0.438 | | PCT (ng/ml) | 14.5 (11.2–31.2) | 18.35 (11.2–31.2) | 0.859 | | MOF (, %) | 23 (85.2) | 61 (64.9) | 0.044 |
| | Sepsis | | | | | (i) Bacteria positive (, %) | 17 (63)
10 (37) | 53 (56.4)
41 (43.6) | 0.542 | | (ii) Bacterial negative (, %) | | | | sNGAL (ng/ml) | 790.99
(623.03–918.38) | 351.86
(262.36–497.86) | <0.001 | | uNGAL (ng/ml) | 885.72
(747.59–1026.51) | 264.68
(128.99–499.02) | <0.001 |
|
|
AKI: acute kidney injury; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; WBC: white blood cell; PCT: procalcitonin; MOF: multiple organ failure; sNGAL: serum neutrophil gelatinase-associated lipocalin; uNGAL: urine neutrophil gelatinase-associated lipocalin.
|
